Endocrinology

Athens, Greece

Endocrinology

Athens, Greece
SEARCH FILTERS
Time filter
Source Type

News Article | May 23, 2017
Site: www.eurekalert.org

Vitamin D supplementation combined with good sleeping habits may help manage pain-related diseases. This paper published in the Journal of Endocrinology, reviews published research on the relationship between vitamin D levels, sleep and pain management, and reports that levels of vitamin D combined with good quality sleep could help manage conditions including arthritis, menstrual cramps and chronic back pain. Although the role of vitamin D in bone metabolism is well-established, there is growing debate on how vitamin D affects a variety of different biological processes, including those related to fertility, infection, pain and sleep. Previously published studies have shown that vitamin D can affect the body's inflammatory response, which also alters pain sensation. Several clinical studies have reported that vitamin D levels are associated with sleep disorders. Chronic pain conditions not only affect sufferers' quality of life but also negatively impact upon health service time and budgets. A link between sleep disturbances and pain has long been established but a role for vitamin D has not been fully investigated. These findings suggest that vitamin D supplementation combined with good sleep quality could increase the effectiveness of pain management treatments, for diverse conditions. This simple approach, if effective, could reduce the burden on health services and improve the lives of patients. This review by Dr Monica Levy Andersen and colleagues at Universidade Federal de Sao Paulo, pulls together and reviews the most relevant studies that have examined the role of vitamin D in pain-related conditions or sleep disturbances. Investigation of these data indicate that vitamin D levels may have an important role in the relationship between pain and sleep, and further highlight how important it is for health professionals to consider the sleep-pain-vitamin D inter-relationship in a variety of pain-related conditions, such as arthritis, chronic back pain and menstrual cramps. Dr Monica Levy Andersen says, "we can hypothesize that suitable vitamin D supplementation combined with sleep hygiene may optimize the therapeutic management of pain-related diseases, such as fibromyalgia" "It is necessary to understand the possible mechanisms involved in this relationship, including immunological and neurobiological pathways related to inter-relationship among sleep, vitamin D and pain", explains Dr Andersen. Assistant Professor Sof Andrikopoulos, University of Melbourne and Editor of the Journal of Endocrinology commented, "this research is very exciting and novel. We are unravelling the possible mechanisms of how vitamin D is involved in many complex processes, including what this review shows - that a good night's sleep and normal levels of vitamin D could be an effective way to manage pain."


NEW YORK, May 23, 2017 (GLOBE NEWSWIRE) -- Dr. Jaime Steinsapir, Endocrinologist at Palm Beach Diabetes and Endocrine Specialists, PA has been selected to join the Physician Board at the American Health Council. He will be sharing his knowledge and expertise in Thyroid Disease and Diabetes. Amassing over four decades in the field, Dr. Steinsapir excels in his current role as an Endocrinologist at Palm Beach Diabetes and Endocrine Specialists, PA. Serving multiple locations in Florida, Palm Beach Diabetes and Endocrine Specialists, PA is a pioneer in the fight against diabetes and other endocrine disorders, through patient education, goal setting, and individual involvement in a personalized treatment program. Each board-certified physician has extensive clinical practice, research, and teaching experience in endocrinology, diabetes and metabolism. Board Certified in Endocrinology, Diabetes and Metabolism and Internal Medicine by the American Board of Internal Medicine, Dr. Steinsapir specializes in the treatment of diabetes, thyroid disease and other metabolic disorders. His day-to-day responsibilities include teaching students and residents at the University of Miami, seeing twenty-five patients per day, conducting clinical trials, and conducting research on diabetes and thyroid disease. Following graduation summa cum laude with a medical degree from the University of Chile in 1975, Dr. Steinsapir earned his PhD in Endocrinology with distinction from the Medical College of Georgia in 1988. Subsequently, he completed a clinical endocrine fellowship at the Brigham and Women's Hospital in 1999.  He is a Fellow of the American College of Physicians and Fellow of the American Association of Clinical Endocrinology. Dr. Steinsapir maintains a membership with The American Association of Clinical Endocrinologists, The American College of Physicians, The American Diabetes Association, The American Society of Internal Medicine, The American Board of Internal Medicine, and The International Society for Clinical Densitometry. Looking back, Dr. Steinsapir attributes his success to receiving support from his family. His desire to pursue a career in healthcare developed after being inspired by his father, a fellow physician. In his free time, Dr. Steinsapir enjoys playing chess and traveling. Considering the future, Dr. Steinsapir hopes to expand his office and to continue teaching. The American Health Council is the nation’s only organization with a constituency representative of all sectors of the healthcare industry. From the coasts to the heartland, the American Health Council has drawn Affiliates from major metropolitan hubs and small communities. These Affiliates span generations and have reached different stages of their careers — from recent graduates to retirees. More information about the American Health Council and its mission can be found at: http://americanhealthcouncil.org Additionally, the American Health Council strives to provide recognition and support for those individuals and institutions making the difference in patients’ lives day in and day out. Throughout 2017, the AHC is honoring “America’s Best Doctors and Nurses,” as well as the nation’s best medical universities and hospitals. The American Health Council’s “Best in Medicine” and “Best in Nursing” awards programs honor the individuals and institutions that have contributed significantly to medicine and nursing, as well as the training and education of physicians and nurses. The most current selections for these honors may be viewed here: http://bestinmedicine.org and http://bestinnursing.org.


News Article | May 25, 2017
Site: www.prnewswire.co.uk

Whilst providing a platform for the peer-reviewed content from our industry-leading journals, touchENDOCRINOLOGY.com also provides physicians, clinicians and other healthcare professionals with the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Editorials, special reports, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Multimedia also features including podcasts and carefully selected videos, developed in house and from our media partners, to further aide easy and effective learning. "I'm excited to announce that The Obesity Society have signed a media agreement with touchENDOCRINOLOGY," said Barney Kent, Managing Director of Touch Medical Media. "This marks our 15th major partnership and will assist the Obesity Society with creating additional awareness of their annual meeting and mission. It will also increase the reach of touchENDOCRINOLOGY content, which currently is sent to our database of over 32,000 physicians. Our database is growing at a rate of knots which is testament to the quality of free to access content we are producing." touchENDOCRINOLOGY (a division of Touch Medical Media) publishesUS Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. Providing practical opinion to support best practice for busy healthcare professionals.


News Article | May 11, 2017
Site: www.prnewswire.co.uk

Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Jean Claude Mbanya, Juergen Sandow, Wolfgang Landgraf and David R Owens introduce biosynthetic human insulin and insulin analogues as the mainstay of insulin therapy for both type 1 and type 2 diabetes. However, access to human insulin at affordable prices remains a global issue. The world is experiencing an exponential rise in the prevalence of diabetes presenting an urgent need to establish effective diabetes therapy in countries burdened by inadequate health care budgets, malnutrition and infectious diseases. Recombinant human insulin has replaced animal insulins and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable prices able to provide global access to insulin therapy. In many patients, analog insulins can offer additional clinical benefit, although at a considerably higher price thus severely restricting availability in low income countries. The approval process for recombinant human insulins (i.e. biosimilars) and analogue insulins is highly variable in the developing countries in contrast to Europe and in North America, where it is well established within a strict regulatory framework. This review aims to discuss the future access to human insulin therapy in a global context with an ever increasing burden of diabetes and significant economic implications. The full peer-reviewed, open-access article is available here: Disclosure: Jean Claude Mbanya is member of the Sanofi AMESA Diabetes Advisory Board. Juergen Sandow is a consultant to Sanofi Paris and Academic Research Associate. Wolfgang Landgraf is an employee of Sanofi-Aventis Germany. David Owens has received honoraria from Boehringer Ingelheim, Eli Lilly, Sanofi and Takeda for lectures and/or advisory boards. touchENDOCRINOLOGY (a division of Touch Medical Media) publishes European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Providing practical opinion to support best practice for busy healthcare professionals.


Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Stephen C Bain presents a review of the Cellnovo insulin delivery system. Autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency, type 1 diabetes mellitus (T1DM). Insulin therapy is required for people with T1DM to achieve an optimal glycated haemoglobin (HbA1c or A1c) along with controlled dayto- day blood glucose (BG) levels. While a variety of insulin delivery systems are available, factors such as the complexity of dosage calculation based on activity, diet and BG, the effectiveness of insulin delivery, ease of product use and 'human' issues, may affect concordance with treatment (see Table 1).[1],[2] Using an insulin delivery system which suits the patient's lifestyle and addresses issues of delivery reliability may improve concordance and ameliorate BG variability. Continuous subcutaneous insulin infusion (CSII) therapy has been shown to: • ensure accurate insulin delivery leading to improved A1c;[3] • eliminate the unpredicatable effects of intermediate or long-acting insulin;[3] • reduce severe low BG episodes; and[3] • facilitate easier delivery of bolus insulin.[3] The full peer-reviewed, open-access article is available here: Disclosure: Stephen C Bain is a member of the Cellnovo Medical Advisory Board. This article is a short opinion piece and has not been submitted to external peer reviewers, but the questions were reviewed by the Editorial Board before publication. European Endocrinology, a peer-reviewed, open access, bi-annual journal  specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Providing practical opinion to support best practice for busy healthcare professionals. [1] Skovlund SE, Peyrot M, The Diabetes Attitudes, Wishes and Needs (DAWN) Program: A new approach to improving outcomes in diabetes care, Diabetes Spectrum, 2005;18(3):136-42.  [2] Nicolucci A, Kovacs Burns K, Holt RIG, et al., Diabetes Attitudes, Wishes and Needs second study (DAWN 2): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes, Diabetic Medicine, 2013;30(7):767-77. [3] American Diabetes Association, Advantages of Using an Insulin Pump, 2015. Available at: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/advantages-of-using-an-insulin-pump.html  (accessed 3 October 2016).


InfoGlobalData Released Updated Mailing List of Endocrinology Physicians for a Successful Marketing Campaign Endocrinology is a branch of medicine dealing with the endocrine system, its diseases and its specific secretions called endocrine glands and hormones. With the Endocrinologists Mailing Addresses List though you cannot improve the numbers, but can at least offers them the best medical supplies and pharmaceuticals needed for rendering services. Seattle, WA, May 12, 2017 --( InfoGlobalData Endocrinology Physicians Email Marketing List therefore will ensure that it aligns marketing strategies and campaigns, and through online and offline campaigns is able to give medical supplies and pharmaceuticals the exposure it deserves. The data at InfoGlobalData is permission based and perfect for marketing products or services. Reach prospects that are eager to buy products and services through InfoGlobalData. InfoGlobalData provides verified, validated and updated Endocrinology Physicians Email Lists to generate many more qualified leads and clients for a business. Endocrinology Physicians Direct Mailing Lists is one of the excellent prospects for the medical equipment & device suppliers, marketers and others. Get customized Endocrinology Physicians Email Marketing List based on the marketing campaign, one can select multi-channel b2b marketing campaigning to go viral and to expand market presence. Also, Reach Endocrinology Professionals within industries such as, · Endocrinology, Diabetes and Metabolism Physician Email List · Pediatric Endocrinology Physicians Mailing List · Endocrinology Physicians Direct Mailing List · Endocrinology, Diabetes and Metabolism Physician Email List · Endocrinology Physicians Email Addresses · Marketing Lists of Endocrine Doctors · Endocrinology Physicians by Specialty Email List · Endocrinology Users Email List · Endocrinology Physicians Directory List · American Association of Clinical Endocrinologists Mailing List · Endocrinology Clinics in US Email List · Endocrinology - Consultants Directory List · Endocrinology Hospitals in US Mailing List · Endocrinology Physicians Email Marketing List · Endocrinology Physicians and Health Care Professional Email List · And More With data that improves campaigning efficiency, InfoGlobalData Endocrinology Physicians Email Addresses are a must! So make haste and get the Endocrinology Specialists Mailing Lists today! Endocrinology Physicians Email Database are updated on regular basis to ensure the highest accuracy level and tested before the final delivery of Endocrinology Physicians Mailing Lists. About InfoGlobalData: InfoGlobalData offers a highly targeted Opt-in Emails and Mails that helps clients to maximize ROI and improve conversions. They provide organizations of all types and sizes with access to the specialized service and databases necessary to clean, validate, correct and enhance marketing contact lists. InfoGlobalData employs expert data specialists that use the latest technology, daily-updated data, and optimized algorithms to provide qualified data outputs for clients. Their data is updated on an ongoing basis and comes from a variety of trusted sources. InfoGlobalData 113 Cherry St #32134 Seattle, WA 98104-2818 USA Email: sales@infoglobaldata.com Contact: +1 (206) 792 3760 Website: http://www.infoglobaldata.com/ Seattle, WA, May 12, 2017 --( PR.com )-- InfoGlobalData has launched Endocrinology Physicians Mailing Database with all Valid and Verified Lists. Endocrinology Physicians Email Addresses List offers access to one of the most reliable databases in the market with all the key information of prospects from this industry.InfoGlobalData Endocrinology Physicians Email Marketing List therefore will ensure that it aligns marketing strategies and campaigns, and through online and offline campaigns is able to give medical supplies and pharmaceuticals the exposure it deserves. The data at InfoGlobalData is permission based and perfect for marketing products or services. Reach prospects that are eager to buy products and services through InfoGlobalData. InfoGlobalData provides verified, validated and updated Endocrinology Physicians Email Lists to generate many more qualified leads and clients for a business.Endocrinology Physicians Direct Mailing Lists is one of the excellent prospects for the medical equipment & device suppliers, marketers and others. Get customized Endocrinology Physicians Email Marketing List based on the marketing campaign, one can select multi-channel b2b marketing campaigning to go viral and to expand market presence.Also, Reach Endocrinology Professionals within industries such as,· Endocrinology, Diabetes and Metabolism Physician Email List· Pediatric Endocrinology Physicians Mailing List· Endocrinology Physicians Direct Mailing List· Endocrinology, Diabetes and Metabolism Physician Email List· Endocrinology Physicians Email Addresses· Marketing Lists of Endocrine Doctors· Endocrinology Physicians by Specialty Email List· Endocrinology Users Email List· Endocrinology Physicians Directory List· American Association of Clinical Endocrinologists Mailing List· Endocrinology Clinics in US Email List· Endocrinology - Consultants Directory List· Endocrinology Hospitals in US Mailing List· Endocrinology Physicians Email Marketing List· Endocrinology Physicians and Health Care Professional Email List· And MoreWith data that improves campaigning efficiency, InfoGlobalData Endocrinology Physicians Email Addresses are a must! So make haste and get the Endocrinology Specialists Mailing Lists today! Endocrinology Physicians Email Database are updated on regular basis to ensure the highest accuracy level and tested before the final delivery of Endocrinology Physicians Mailing Lists.About InfoGlobalData:InfoGlobalData offers a highly targeted Opt-in Emails and Mails that helps clients to maximize ROI and improve conversions. They provide organizations of all types and sizes with access to the specialized service and databases necessary to clean, validate, correct and enhance marketing contact lists.InfoGlobalData employs expert data specialists that use the latest technology, daily-updated data, and optimized algorithms to provide qualified data outputs for clients. Their data is updated on an ongoing basis and comes from a variety of trusted sources.InfoGlobalData113 Cherry St #32134Seattle, WA 98104-2818USAEmail: sales@infoglobaldata.comContact: +1 (206) 792 3760Website: http://www.infoglobaldata.com/ Click here to view the list of recent Press Releases from InfoGlobalData


Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Jean Claude Mbanya, Juergen Sandow, Wolfgang Landgraf and David R Owens introduce biosynthetic human insulin and insulin analogues as the mainstay of insulin therapy for both type 1 and type 2 diabetes. However, access to human insulin at affordable prices remains a global issue. The world is experiencing an exponential rise in the prevalence of diabetes presenting an urgent need to establish effective diabetes therapy in countries burdened by inadequate health care budgets, malnutrition and infectious diseases. Recombinant human insulin has replaced animal insulins and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable prices able to provide global access to insulin therapy. In many patients, analog insulins can offer additional clinical benefit, although at a considerably higher price thus severely restricting availability in low income countries. The approval process for recombinant human insulins (i.e. biosimilars) and analogue insulins is highly variable in the developing countries in contrast to Europe and in North America, where it is well established within a strict regulatory framework. This review aims to discuss the future access to human insulin therapy in a global context with an ever increasing burden of diabetes and significant economic implications. The full peer-reviewed, open-access article is available here: Disclosure: Jean Claude Mbanya is member of the Sanofi AMESA Diabetes Advisory Board. Juergen Sandow is a consultant to Sanofi Paris and Academic Research Associate. Wolfgang Landgraf is an employee of Sanofi-Aventis Germany. David Owens has received honoraria from Boehringer Ingelheim, Eli Lilly, Sanofi and Takeda for lectures and/or advisory boards. touchENDOCRINOLOGY (a division of Touch Medical Media) publishes European Endocrinology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Providing practical opinion to support best practice for busy healthcare professionals.


Published recently in European Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Stephen C Bain presents a review of the Cellnovo insulin delivery system. Autoimmune destruction of pancreatic beta-cells results in absolute insulin deficiency, type 1 diabetes mellitus (T1DM). Insulin therapy is required for people with T1DM to achieve an optimal glycated haemoglobin (HbA1c or A1c) along with controlled dayto- day blood glucose (BG) levels. While a variety of insulin delivery systems are available, factors such as the complexity of dosage calculation based on activity, diet and BG, the effectiveness of insulin delivery, ease of product use and 'human' issues, may affect concordance with treatment (see Table 1).[1],[2] Using an insulin delivery system which suits the patient's lifestyle and addresses issues of delivery reliability may improve concordance and ameliorate BG variability. Continuous subcutaneous insulin infusion (CSII) therapy has been shown to: • ensure accurate insulin delivery leading to improved A1c;[3] • eliminate the unpredicatable effects of intermediate or long-acting insulin;[3] • reduce severe low BG episodes; and[3] • facilitate easier delivery of bolus insulin.[3] The full peer-reviewed, open-access article is available here: Disclosure: Stephen C Bain is a member of the Cellnovo Medical Advisory Board. This article is a short opinion piece and has not been submitted to external peer reviewers, but the questions were reviewed by the Editorial Board before publication. European Endocrinology, a peer-reviewed, open access, bi-annual journal  specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals. Providing practical opinion to support best practice for busy healthcare professionals. [1] Skovlund SE, Peyrot M, The Diabetes Attitudes, Wishes and Needs (DAWN) Program: A new approach to improving outcomes in diabetes care, Diabetes Spectrum, 2005;18(3):136-42.  [2] Nicolucci A, Kovacs Burns K, Holt RIG, et al., Diabetes Attitudes, Wishes and Needs second study (DAWN 2): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes, Diabetic Medicine, 2013;30(7):767-77. [3] American Diabetes Association, Advantages of Using an Insulin Pump, 2015. Available at: http://www.diabetes.org/living-with-diabetes/treatment-and-care/medication/insulin/advantages-of-using-an-insulin-pump.html  (accessed 3 October 2016).


Baltimore, Md. - May 5, 2017. New research at the University of Maryland School of Medicine (UM SOM) has found that secondhand smoke tends to have somewhat different effects on men and women. The research, conducted in a Pennsylvania Amish community where virtually no women smoke, found that women who were exposed to secondhand smoke had a greater risk for cardiovascular disease, while men exposed to secondhand smoke tended to have a higher body mass index (BMI). The authors of the study, published in the journal PLoS ONE, say previous research on the effects of secondhand smoke, and smoking in general, have been difficult to interpret due to variables in the socioeconomic status and educational level of participants. To reduce these variables, the researchers studied members of the old order Amish (OOA), a community in Lancaster County, Pa. UM SOM research teams have conducted research in this community since 1995 through the UM SOM's Amish Research Program. "The way the Amish live makes them uniquely suited for this kind of study," says lead investigator Robert M. Reed, MD, UM SOM associate professor of medicine and a pulmonary and critical care specialist at the University of Maryland Medical Center. "They live a lifestyle now that's very similar to the lifestyle their ancestors lived many generations ago. They have a lot of physical activity, don't drive, and the different Amish families live more similar lifestyles than do non-Amish populations." Also unique, cigars and pipes represent the predominant forms of tobacco smoked by the Amish. Reed says these smoking products produce more noxious secondhand smoke than cigarettes. Smoking in the group as a whole is fairly modest - 34 percent of men in the study said they had ever smoked. Just two women in the group reported ever smoking. The researchers employed a novel method to track exposure to secondhand smoke. "We first asked people their own personal smoking habits, and then, because we know exactly how all the Amish are related to each other, we were able to look at the family tree and extrapolate who had been exposed," explains Reed. "We knew if Mr. X says he smoked, we can extrapolate from that that his family was exposed." According to Reed, this approach has never been taken before in studies of smoking and it avoids a problem that can affect this type of research, called recall bias. "Sometimes people with poor health are more inclined to think harder about past exposures, which lead to misleading results. Our study avoids that possibility," Reed says. The researchers examined cross-sectional data on 3,568 Amish who participated in three community surveys of cardiovascular health between 2001 and 2015. Data included tobacco use and secondhand smoke exposure from family members included in the study. Additionally, the researchers took blood samples, measured lung function and assessed vascular health. Smoking, which was limited to just men, was associated with lower lung function, higher BMI, lower HDL cholesterol (the "good" cholesterol), higher heart rate and poorer vascular health. The impact of secondhand smoke exposure was more intense in people with more smokers in their families, including spouses, parents and siblings. Secondhand smoke was associated with higher BMI and with higher fasting glucose in men, suggesting a diabetes risk, but not in women. Reduced HDL cholesterol was seen only in women exposed to secondhand smoke; in men only, secondhand smoke was associated with a lower heart rate. "The study confirms that even a small amount of secondhand smoke is harmful; it confirms prior findings and extends them by adding to the degree of certainty we have in the harmful associations we are seeing," says Reed. He adds that the findings suggest the possibility of a significant role for mechanisms less clearly established in secondhand smoking, but recognized in association with active smoking, such as HDL and BMI. "The real strength of this study is that this is a big population with very low exposure, yet we see very striking results for direct exposure," says the study's senior author, Braxton D. Mitchell, PhD, MPH, professor of medicine, epidemiology and public health at the University of Maryland School of Medicine and vice chair for research in the Division of Endocrinology, Diabetes & Nutrition in the Department of Medicine. "I would not have expected to see such dramatic effects with these low exposures." E. Albert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the School of Medicine, says, "This study suggests new avenues of research to understand more about the underlying mechanisms behind secondhand smoke. The fact that small amounts of exposure caused significant impact among Amish non-smokers, a population in which smoking is already at low levels, should be of concern to populations where smoking is much more prevalent." Tobacco smoking is the leading preventable cause of death in the United States, responsible for an estimated 480,320 deaths annually, including 41,280 deaths attributable to lung cancer and coronary heart disease related to secondhand smoke exposure, according to a 2014 report from the Office of the Surgeon General. Reed RM, Dransfield MT, Eberlein M, Miller M, Netzer G, Pavlovich M, Pollin TI, Scharf SM, Shuldiner AR, Sin D, Mitchell BD. "Gender differences in first and secondhand smoke exposure, spirometric lung function and cardiometabolic health in the old order Amish: A novel population without female smoking." PLoS ONE. 12(3): e0174354 March 31, 2017. doi:10.1371/journal.pone.0174354 Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States. It continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Maryland's Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world. http://medschool. . The University of Maryland Medical Center (UMMC) is comprised of two hospitals in Baltimore: an 800-bed teaching hospital - the flagship institution of the 12-hospital University of Maryland Medical System (UMMS) - and a 200-bed community teaching hospital, UMMC Midtown Campus. UMMC is a national and regional referral center for trauma, cancer care, neurocare, cardiac care, diabetes and endocrinology, women's and children's health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the flagship hospital are faculty physicians of the University of Maryland School of Medicine. At UMMC Midtown Campus, faculty physicians work alongside community physicians to provide patients with the highest quality care. UMMC Midtown Campus was founded in 1881 and is located one mile away from the University Campus hospital. For more information, visit http://www. .


News Article | May 9, 2017
Site: www.eurekalert.org

DALLAS - May 9, 2017 - UT Southwestern research investigating the blood glucose-regulatory actions of the hormone ghrelin may have implications for development of new treatments for diabetes. Blood glucose is tightly regulated by the opposing actions of the hormones insulin and glucagon. Earlier studies led by Dr. Roger Unger, Professor of Internal Medicine at UT Southwestern Medical Center, demonstrated that experimentally deleting or neutralizing receptors for glucagon can prevent or correct dangerously high blood glucose levels in different models of diabetes. "Dr. Unger's research suggested that high or unopposed glucagon action that results from insulin deficiency is the main culprit in the development of high blood glucose - known as hyperglycemia - in diabetes," said Dr. Jeffrey Zigman, Professor of Internal Medicine and Psychiatry at UT Southwestern and senior author of the study, published online today in the journal Diabetes. "He proposed that blocking or neutralizing glucagon action may serve as a new treatment for Type 1 and Type 2 diabetes. This idea formed the basis of our current study," Dr. Zigman added. Like glucagon and insulin, ghrelin also plays an important role in blood glucose control. But because the hormone was only discovered in the 1990s, ghrelin's actions on blood glucose haven't been studied as much as those of glucagon and insulin. The UTSW research team wanted to learn more about the role of ghrelin in diabetes. "We studied mice that lacks glucagon receptors. When we tried to make these animals diabetic by giving them an agent that destroys insulin-producing cells, the mice did not develop diabetes. Their blood sugar was normal. In addition to these results, we found that their ghrelin levels were high," said Dr. Zigman, who holds the Kent and Jodi Foster Distinguished Chair in Endocrinology, in Honor of Daniel Foster, M.D., the Mr. and Mrs. Bruce G. Brookshire Professorship in Medicine, and The Diana and Richard C. Strauss Professorship in Biomedical Research. In a related set of studies, when the researchers blocked the action of the elevated ghrelin, doing so caused the animals' blood sugar levels to drop below normal, he added. "These findings suggest that when glucagon activity is blocked, circulating levels of ghrelin rise, which helps to prevent dangerously low blood sugars from developing, a condition known as hypoglycemia," Dr. Zigman said. Pharmaceutical companies are now developing drugs targeting glucagon receptors to treat diabetes, including antibodies that will neutralize glucagon receptors or drugs that will block glucagon receptors, he added. "The body's normal ghrelin response should protect diabetic individuals being treated with agents that target glucagon receptors from experiencing hypoglycemia," Dr. Zigman said. Since the current study focused on a Type 1 diabetes model, researchers next plan to examine the coordinated actions of the ghrelin and glucagon systems in a Type 2 diabetes model. They also want to study the impact of ghrelin on hypoglycemia. "A potential side effect with any treatment that lowers blood sugar is that hypoglycemia may develop," Dr. Zigman said. "We would like to determine whether the administration of ghrelin or a compound that mimics the action of ghrelin could help correct that hypoglycemia." Lead author of the study is Dr. Bharath Mani, Instructor of Internal Medicine, and the co-senior authors include Dr. Unger, who holds the Touchstone/West Distinguished Chair in Diabetes Research, and Dr. Eric Berglund, Assistant Professor in the Advanced Imaging Research Center and of Pharmacology. Other contributing UTSW researchers are Dr. Aki Uchida, postdoctoral research fellow; Dr. Young Lee, Assistant Professor of Internal Medicine; and Sherri Osborne-Lawrence, senior research scientist. The study received support from the National Institutes of Health, the Novo Nordisk Foundation Center for Basic Metabolic Research, and the Hilda & Preston Davis Foundation. UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 18 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year. This news release is available on our website at http://www. . To automatically receive news releases from UT Southwestern via email, subscribe at http://www. .

Loading Endocrinology collaborators
Loading Endocrinology collaborators